Navigation Links
Questcor to Present at the Maxim Group Growth Conference

ANAHEIM, Calif., Nov. 16, 2010 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that it will present at the Maxim Group Growth Conference at 4:00 p.m. ET on Thursday, November 18, 2010 at the Grand Hyatt Hotel in New York. Don M. Bailey, President and Chief Executive Officer, will review the Company's business strategy and recent corporate developments.

Attendance at this conference is by invitation only. A live audio and slides webcast of Questcor's presentation may be accessed through the Company's website at An archived replay of the presentation will be available for 90 days after the live presentation, and can also be accessed at

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from two indications: the treatment of acute exacerbations of multiple sclerosis in adults and the treatment of infantile spasms in children under two years of age.  Questcor is also implementing plans to commercialize Acthar for use in treating nephrotic syndrome, another on-label indication. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Reports Third Quarter 2010 Results
2. Questcor to Present at the 21st Annual Oppenheimer Healthcare Conference
3. Questcor Teams With Child Neurology Foundation (CNF) to Fund Infantile Spasms Scientific Research
4. Questcor and Child Neurology Foundation Support the 2nd Annual Infantile Spasms (IS) Awareness Week
5. Questcor to Present at UBS Global Life Sciences Conference
6. Mitchell J. Blutt, M.D. Appointed to Questcor Board of Directors
7. Questcor Receives Notification of PDUFA Date Extension to September 11, 2010
8. Questcor to Present at the Jefferies 2010 Global Life Sciences Conference
9. Trading Halted Today in Questcor Pharmaceuticals Common Stock
10. Questcor to Discuss Results From FDA Panel Meeting
11. Questcor Reports Solid Fourth Quarter Results
Post Your Comments:
(Date:12/1/2015)... Ohio , Dec. 1, 2015 ... to its GeneSight® Psychotropic test giving healthcare providers an ... medication decisions for patients suffering from depression, anxiety, ... other behavioral health conditions. i ... --> With the addition of two ...
(Date:12/1/2015)... 2015 --> ... "Nucleic Acid Labeling Market by Product (Reagents & Kits, ... In Vitro Transcription, Reverse Transcription, End Labeling), by Region ... global market is expected to reach USD 1,925.7 Million ... at a CAGR of 8.65%. Browse 77 ...
(Date:12/1/2015)... , Dec. 01, 2015 ... the "Veterinary Equipment and Disposables Market by ... report to their offering. --> ... "Veterinary Equipment and Disposables Market by product, ... report to their offering. --> Research ...
Breaking Medicine Technology:
(Date:12/1/2015)... TX (PRWEB) , ... December 01, 2015 , ... Dr. ... of Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best Single ... of the best among the many elite aesthetic physicians honored by the industry publication. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... have seen vast improvements in scientific research and discoveries, leading us to better ... hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform edition of “World ...
(Date:12/1/2015)... ... December 01, 2015 , ... Diabetic foot ... States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience of a health ... contributors to diseases of the diabetic foot. The American Board of Multiple ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. ... results enhancements at the Radiological Society of North America (RSNA) 2015 annual meeting ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced ... the United States. Clarity is a Superior Dual Wavelength Platform which combines two ... platform that is easy to own and operate. , For over a decade, ...
Breaking Medicine News(10 mins):